Insider Buying Continues Amidst a Quiet Market The latest Form 4 filing from Phio Pharmaceuticals Corp. shows owner Patricia A. Bradford purchasing 12,000 shares of common stock on September 15, 2026. The transaction was executed at $1.03 per share, a price virtually unchanged from the closing price of $1.02 the previous day, indicating a neutral market view of the trade. The purchase was part of a broader pattern of insider buying that has characterized the company’s leadership over the past year, with several senior executives, including the Chairman, President and CEO, making substantial acquisitions in late August and early September.
What the Buy Signals for Investors While the trade itself is modest relative to the overall shareholder base—just over 0.1 % of the post‑transaction holdings—its timing and consistency suggest confidence from insiders in Phio’s long‑term prospects. The company’s share price has been on a downtrend, falling 52.65 % year‑to‑date and trading near its 52‑week low, yet the steady insider purchases hint at an expectation of future upside. For investors, this can be read as a subtle endorsement that the company’s oncology pipeline and strategic initiatives may be gaining traction, even if the market has yet to fully price in those developments.
Profile of Patricia A. Bradford Patricia A. Bradford’s insider activity dates back to at least February 2025, when she first acquired 18,800 shares. Over the past eighteen months she has executed three purchases totaling 49,300 shares, bringing her stake to 57,651 shares as of the latest filing. Her transactions have always been at or near the market price, with no accompanying sales. This pattern—steady, price‑matched buying without divestiture—indicates a long‑term commitment rather than speculative trading. Bradford’s holdings are sizable enough to grant her meaningful influence within the company’s governance structure, yet not so large as to trigger significant regulatory scrutiny.
Insider Activity in Context The broader insider landscape at Phio reflects a mix of buying and selling by senior executives. While the CFO and CEO recently sold shares in September, their holdings remain substantial, and other insiders, such as the CFO, have continued to add to their positions. The recent buying spree by Bradford and the CEO in August and early September suggests that insiders are aligning their interests with the company’s performance trajectory, potentially in anticipation of upcoming clinical milestones or regulatory approvals.
Implications for the Future For seasoned investors and market analysts, the trend of insider buying—despite a challenging share price environment—offers a signal of confidence from those closest to Phio’s strategic direction. If the company can sustain its research and development momentum, especially in its cancer immunotherapy portfolio, the insider optimism may translate into a rebound in share value. Conversely, should the company face setbacks, the relatively low level of insider sales suggests that executives may be willing to absorb short‑term volatility in pursuit of long‑term gains.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-09-15 | BRADFORD PATRICIA A () | Buy | 12,000.00 | 1.03 | Common Stock, $.0001 par value |
